Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

Similar articles for PubMed (Select 24518104)

1.

Ureaplasma, bronchopulmonary dysplasia, and azithromycin in European neonatal intensive care units: a survey.

Pansieri C, Pandolfini C, Elie V, Turner MA, Kotecha S, Jacqz-Aigrain E, Bonati M.

Sci Rep. 2014 Feb 12;4:4076. doi: 10.1038/srep04076.

PMID:
24518104
2.

Azithromycin and other macrolides for prevention of bronchopulmonary dysplasia: a systematic review and meta-analysis.

Nair V, Loganathan P, Soraisham AS.

Neonatology. 2014;106(4):337-47. doi: 10.1159/000363493. Epub 2014 Oct 1.

3.

Pharmacokinetics, safety, and biologic effects of azithromycin in extremely preterm infants at risk for ureaplasma colonization and bronchopulmonary dysplasia.

Hassan HE, Othman AA, Eddington ND, Duffy L, Xiao L, Waites KB, Kaufman DA, Fairchild KD, Terrin ML, Viscardi RM.

J Clin Pharmacol. 2011 Sep;51(9):1264-75. doi: 10.1177/0091270010382021. Epub 2010 Nov 23.

5.

Critical appraisal of the role of Ureaplasma in the development of bronchopulmonary dysplasia with metaanalytic techniques.

Schelonka RL, Katz B, Waites KB, Benjamin DK Jr.

Pediatr Infect Dis J. 2005 Dec;24(12):1033-9.

PMID:
16371861
6.

Azithromycin to prevent bronchopulmonary dysplasia in ureaplasma-infected preterm infants: pharmacokinetics, safety, microbial response, and clinical outcomes with a 20-milligram-per-kilogram single intravenous dose.

Viscardi RM, Othman AA, Hassan HE, Eddington ND, Abebe E, Terrin ML, Kaufman DA, Waites KB.

Antimicrob Agents Chemother. 2013 May;57(5):2127-33. doi: 10.1128/AAC.02183-12. Epub 2013 Feb 25.

7.

Incidence of bronchopulmonary dysplasia in Korea.

Choi CW, Kim BI, Kim EK, Song ES, Lee JJ.

J Korean Med Sci. 2012 Aug;27(8):914-21. doi: 10.3346/jkms.2012.27.8.914. Epub 2012 Jul 25. Erratum in: J Korean Med Sci. 2012;27(10):1282.

8.

Survey of the use of corticosteroids among neonatal intensive care units for the prevention or treatment of bronchopulmonary dysplasia.

Porter KB, Garner SS.

J Pediatr Pharmacol Ther. 2005 Apr;10(2):90-9. doi: 10.5863/1551-6776-10.2.90.

10.

[Clinical significance of Ureaplasma urealyticum in bronchopulmonary dysplasia of prematurity].

Bao Y, Zhao ZY, Shi LP, Ma XL, Chen Z, Luo F.

Zhonghua Er Ke Za Zhi. 2012 Oct;50(10):767-70. Chinese.

PMID:
23302568
11.

Higher altitude and risk of bronchopulmonary dysplasia among preterm infants.

Lee SK, Ye XY, Singhal N, De La Rue S, Lodha A, Shah PS; Canadian Neonatal Network.

Am J Perinatol. 2013 Aug;30(7):601-6. doi: 10.1055/s-0032-1329690. Epub 2012 Nov 12.

PMID:
23147080
12.

Use of azithromycin for the prevention of bronchopulmonary dysplasia in preterm infants: a randomized, double-blind, placebo controlled trial.

Ballard HO, Shook LA, Bernard P, Anstead MI, Kuhn R, Whitehead V, Grider D, Crawford TN, Hayes D Jr.

Pediatr Pulmonol. 2011 Feb;46(2):111-8. doi: 10.1002/ppul.21352. Epub 2010 Oct 20.

PMID:
20963840
13.

Azithromycin, Ureaplasma and chronic lung disease of prematurity: a case study for neonatal drug development.

Turner MA, Jacqz-Aigrain E, Kotecha S.

Arch Dis Child. 2012 Jun;97(6):573-7. doi: 10.1136/adc.2010.195180. Epub 2011 Jun 22. Review.

PMID:
21697219
14.

Rate of bronchopulmonary dysplasia as a function of neonatal intensive care practices.

Van Marter LJ, Pagano M, Allred EN, Leviton A, Kuban KC.

J Pediatr. 1992 Jun;120(6):938-46.

PMID:
1593356
15.

Site-specific characteristics of infants developing bronchopulmonary dysplasia.

Akram Khan M, Kuzma-O'Reilly B, Brodsky NL, Bhandari V.

J Perinatol. 2006 Jul;26(7):428-35. Epub 2006 May 18. Erratum in: J Perinatol. 2006 Aug;26(8):524.

PMID:
16724120
16.

Are preterm infants at high altitude at greater risk for the development of bronchopulmonary dysplasia?

Alshehri MA.

J Trop Pediatr. 2014 Feb;60(1):68-73. doi: 10.1093/tropej/fmt079. Epub 2013 Sep 26.

PMID:
24072557
17.

Single nucleotide polymorphism in toll-like receptor 6 is associated with a decreased risk for ureaplasma respiratory tract colonization and bronchopulmonary dysplasia in preterm infants.

Winters AH, Levan TD, Vogel SN, Chesko KL, Pollin TI, Viscardi RM.

Pediatr Infect Dis J. 2013 Aug;32(8):898-904. doi: 10.1097/INF.0b013e31828fc693.

18.

Wide intra- and inter-country variability in drug use and dosage in very-low-birth-weight newborns with severe infections.

Pandolfini C, Kaguelidou F, Sequi M, Jacqz-Aigrain E, Choonara I, Turner MA, Manzoni P, Bonati M.

Eur J Clin Pharmacol. 2013 Apr;69(4):1031-6. doi: 10.1007/s00228-012-1415-2. Epub 2012 Oct 5.

19.

Nonventilatory strategies for prevention and treatment of bronchopulmonary dysplasia--what is the evidence?

Thomas W, Speer CP.

Neonatology. 2008;94(3):150-9. doi: 10.1159/000143719. Epub 2008 Aug 1. Review.

PMID:
18679037
20.

Ureaplasma in lung. 2. Association with bronchopulmonary dysplasia in premature newborns.

Benstein BD, Crouse DT, Shanklin DR, Ourth DD.

Exp Mol Pathol. 2003 Oct;75(2):171-7.

PMID:
14516781
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk